Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Maravai LifeSciences (MRVI) shares

Learn how to easily invest in Maravai LifeSciences shares.

Maravai LifeSciences is a biotechnology business based in the US. Maravai LifeSciences stocks (MRVI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $38.75 – a decrease of 19.35% over the previous week. Maravai LifeSciences employs 460 staff and has a trailing 12-month revenue of around $669.1 million.

How to buy shares in Maravai LifeSciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRVI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Maravai LifeSciences stock price (NASDAQ:MRVI)

Use our graph to track the performance of MRVI stocks over time.

Maravai LifeSciences shares at a glance

Information last updated 2022-01-18.
Latest market close$24.46
52-week range$27.71 - $63.55
50-day moving average $38.81
200-day moving average $42.30
Wall St. target price$58.13
PE ratio 6.4354
Dividend yield N/A (0%)
Earnings per share (TTM) $4.71

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Maravai LifeSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Maravai LifeSciences price performance over time

Historical closes compared with the close of $24.46 from 2022-01-21

1 week (2022-01-14) -19.35%
1 month (2021-12-23) -41.76%
3 months (2021-10-22) -41.76%
6 months (2021-07-23) -41.76%
1 year (2021-01-22) -21.83%
2 years (2020-01-19) N/A
3 years (2019-01-19) N/A
5 years (2017-01-19) N/A

Is Maravai LifeSciences under- or over-valued?

Valuing Maravai LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Maravai LifeSciences's P/E ratio

Maravai LifeSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Maravai LifeSciences shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Maravai LifeSciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Maravai LifeSciences's EBITDA

Maravai LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $450.4 million.

The EBITDA is a measure of a Maravai LifeSciences's overall financial performance and is widely used to measure a its profitability.

To put Maravai LifeSciences's EBITDA into context you can compare it against that of similar companies.

Maravai LifeSciences financials

Revenue TTM $669.1 million
Operating margin TTM 63.3%
Gross profit TTM $204.4 million
Return on assets TTM 7.02%
Return on equity TTM 52.65%
Profit margin 22.69%
Book value $2.30
Market capitalisation $4 billion

TTM: trailing 12 months

Maravai LifeSciences share dividends

We're not expecting Maravai LifeSciences to pay a dividend over the next 12 months.

You may also wish to consider:

Maravai LifeSciences overview

Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site